Medication for the treatment of diseases of the urinary tract :: Consumers survey results of for 3 quarter of 2016

Consumers survey results of for 3 quarter of 2016 in category

Gynecology, urology, nephrology / Medication for the treatment of diseases of the urinary tract

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.	3	Урохолум (Vishpha \| Фармацевтична фабрика Vishpha)	42.86%	5

2.	1	Уролесан (Arterium Corporation)	35.71%	4.17

3.	2	Канефрон Н (Bionorica)	32.14%	3.75

4.	5	Нефрофіт (Aim)	14.29%	1.67

5.		Блемарен (Esparma)	10.71%	1.25

6.	4	Берёзы почки (Ternopharm)	7.14%	0.83

7.	3	Афлазин (Валартін Фарма)	3.57%	0.42

7.	~	Уронат Медивит (Naturprodukt Vega (Dr. Theiss Naturwaren GmbH))	3.57%	0.42

7.	5	Уростон (Progress pharma)	3.57%	0.42

7.	4	Цистон (Фірма ТК Комфорт)	3.57%	0.42

–.		Diurol (Валартін Фарма)	0.00%	0

–.	5	Nephrocare (Delta Medical)	0.00%	0

–.		Уро-Ваксом (Astellas Europe)	0.00%	0

–.		Уро-гран (Національна гомеопатична спілка)	0.00%	0

–.	5	Фітолізин Плюс (Farmak)	0.00%	0

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2016, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.